The excitement around Moderna’s cancer vaccine is cooling. Here’s why.
Investors had “incredibly high” expectations around the Phase 3 data for the drugmaker’s experimental cancer treatment.
Covered in this story
Analyst targets on Moderna
- Citi: $193 → $80 by Sep 2027 · Sell via 247wallst.com
- Rothschild & Co Redburn: $149 → $81 by Sep 2027 · Sell via Investing.com
- Morgan Stanley: $174 → $89 by Aug 2027 · Equalweight via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $MRNA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Moderna →Dalsna Finance is currently tracking 13 stories mentioning Moderna, the earliest published 21 Oct 2026.
Summary aggregated from MarketWatch's public RSS feed. The full reporting belongs to MarketWatch — please read it on their site.